Latest Breaking News On - சுவாச தோல்வி - Page 3 : comparemela.com

 E-Mail Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology s 70th Annual Scientific Session. The researchers, while acknowledging the results were not statistically significant, said they were encouraged by the lower numbers of organ failure and deaths observed in patients treated with dapagliflozin and by favorable safety data. COVID-19 can lead to multi-organ failure, especially in patients at high risk for severe illness and complications. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial was the first phase III randomized, controlled clinical trial that was initiated to determine whether dapagliflozin could reduce cardiovascular, kidney and respiratory complications

Saint lukeUnited statesMikhail kosiborodNicole napoliYann nguyenResearch at saint luke health systemSaint luke mid america heart instituteAmerican college of cardiologyAmerican collegeAnnual scientificRespiratory failureMid america heart instituteHealth systemKansas cityMajor clinical eventsதுறவி லூக்